S-1/A: iSpecimen Inc. Files Amended S-1 for Up to $4 Million Public Offering Amidst 'Going Concern' Warning

Sentiment:

Registration Statement Amendment 27 June 2025 4:30 PM

iSpecimen Inc. has filed an amended S-1 registration statement for a public offering of up to $4 million in common stock and pre-funded warrants, aiming to secure capital for marketing, technology acquisition, and general corporate purposes, amidst a 'going concern' warning from its auditors.

Capital raiseThe company is offering up to $4,000,000 worth of common stock and/or pre-funded warrants on an underwritten basis.The offering is being underwritten on a firm commitment basis by WestPark Capital, Inc., acting as the sole book-runner.The purchase price of each Pre-Funded Warrant will be equal to the price per Share, minus $0.0001, with a remaining exercise price of $0.0001 per share.The net proceeds from the offering are estimated to be approximately $_________ (placeholder in document) after deducting underwriting fees and expenses, assuming the full offering amount is raised.The company believes the net proceeds from this offering, together with existing cash, will be sufficient to fund operations for at least six months.

Worse than expectedThe company's independent registered public accounting firm, Wolf & Company, P.C., included an explanatory paragraph in their report for the fiscal year ended December 31, 2023, indicating 'substantial doubt about the ability of the Company to continue as a going concern.'The historical net tangible book value as of December 31, 2024, was approximately $(2,017,646) million, or $(1.19) per share, indicating a negative equity position.The necessity of this capital raise, with proceeds allocated to marketing, technology acquisition, and general working capital, suggests the company requires external funding to sustain operations and address its critical financial position.

Summary

iSpecimen Inc. is conducting an underwritten public offering of up to $4,000,000 in common stock and/or pre-funded warrants, with an assumed public offering price of $_____ per share.
The company operates a global marketplace platform connecting life science researchers to human biospecimens and associated data.
The net proceeds from the offering are estimated to be approximately $_________ (assuming the full offering amount is raised) after deducting underwriting fees and expenses.
Proceeds will be allocated as follows: approximately $1,500,000 for marketing and advertising services by IR Agency LLC, $1,000,000 for an initial milestone payment to Sales Stack Solutions Corp. for technology platform acquisition, and the remaining net proceeds for working capital and general corporate purposes.
The company's auditor, Wolf & Company, P.C., included an explanatory paragraph in their report for the fiscal year ended December 31, 2023, regarding 'substantial doubt about the ability of the Company to continue as a going concern.'
As of December 31, 2024, the company's historical net tangible book value was approximately $(2,017,646) million, or $(1.19) per share, based on 1,696,904 shares outstanding.
As of December 31, 2024, the company's supply network consisted of approximately 76 unique healthcare organizations and biospecimen providers across 11 countries.
From inception through December 31, 2024, iSpecimen had distributed over 240,000 specimens to approximately 765 customers in 23 countries.
Customer retention for top 25 customers from 2023 to 2024 was 64%.
Revenue contribution in 2023 and 2024 was primarily from Research Use Only tissue (47%) and Research Use Only biofluids (39%), with Remnant biofluids contributing 13%.

Sentiment

Score: 4

Explanation: The company is undertaking a crucial capital raise to address its financial needs, as evidenced by the 'going concern' warning and negative net tangible book value. While the offering aims to fund strategic growth initiatives and extend operational runway, the underlying financial fragility and the necessity of the raise temper overall sentiment. The business model and market position are positive, but execution and financial stability remain key concerns.

Positives

Established global marketplace platform (iSpecimen Marketplace) connecting researchers to biospecimens and data, designed to address a fragmented and inefficient market.
Extensive supply network of approximately 76 healthcare organizations and biospecimen providers in 11 countries, built over a ten-year period.
Diverse customer base of approximately 765 customers across biopharmaceutical, in vitro diagnostic, and government/academic institutions.
High volume of specimens distributed, exceeding 240,000 since inception through December 31, 2024, to 23 countries.
Strong customer retention rate of 64% for top 25 customers from 2023 to 2024, indicating recurring business relationships.
Strategic use of proceeds for marketing and technology acquisition aims to enhance platform functionality, improve operational efficiency, and expand market reach.
The company's 'just in time' procurement business model offers advantages over traditional inventory-based suppliers by avoiding inventory risks and lengthy cash conversion cycles.
The iSpecimen Marketplace technology is described as groundbreaking in the human biospecimen procurement space, offering a more efficient user experience.

Negatives

The company's independent registered public accounting firm, Wolf & Company, P.C., included an explanatory paragraph in their report for the fiscal year ended December 31, 2023, indicating 'substantial doubt about the ability of the Company to continue as a going concern.'
Historical net tangible book value as of December 31, 2024, was negative, at approximately $(2,017,646) million or $(1.19) per share.
The offering will result in immediate dilution to new investors purchasing shares of common stock.
Significant customer concentration, with one customer accounting for approximately 29% of total revenue in 2024 and 25% in 2023.
Significant supplier concentration, with one supplier accounting for 11.3% of total cost of revenue in 2024 and 12.7% in 2023.
There is no established public trading market for the Pre-Funded Warrants, and the company does not intend to apply for listing, which will limit their liquidity.
Management will have broad discretion in the application of the net proceeds, meaning investors will rely on their judgment regarding fund allocation.
The $1,500,000 payment to IR Agency LLC for marketing services is due in full upon closing and is non-refundable if the company terminates the agreement during the initial three-month term.

Risks

The company's ability to enter into contracts with healthcare providers to gain access to specimens, subjects, and data on favorable terms.
The company's ability to obtain new customers and retain existing customers.
The risk that technology development may not adequately keep pace to support expansion of existing business or entry into new lines of businesses.
The market adoption rate of the iSpecimen Marketplace technology.
The company's ability to continue to expand outside of the United States in compliance with local laws and regulations.
The acceptance of the products and services marketed by the company.
The viability of the company's current intellectual property.
Compliance with government regulations, which can be complex and subject to change.
The company's ability to retain key employees, which is crucial for operations and growth.
Adverse changes in general market conditions for biospecimens.
The company's ability to generate sufficient cash flow and profitability to continue as a going concern.
Uncertainty regarding future financing plans and the potential for further dilution if additional capital is raised through the sale of equity or convertible debt securities.
The company's ability to adapt to changes in market conditions which could impair operations and financial performance.
Reliance on third parties for certain technology to support platform development, delivery, and operations.
Potential alternative characterizations of Pre-Funded Warrants by the IRS, which could change the amount and character of a U.S. Holder's gain.
The possibility that the company could be classified as a United States real property holding corporation, impacting Non-U.S. Holders.

Future Outlook

iSpecimen plans to continue enhancing its iSpecimen Marketplace platform by improving customer experience, increasing supplier engagement, and improving operational efficiency. Future developments include increased patient and specimen data integration, improved matchmaking, direct support for prospective collections, deeper search and workflow capabilities, increased automation, and direct pricing availability. The company also explores adjacencies leveraging the platform, such as a 'data as a product' model. The net proceeds from this offering, combined with existing cash, are expected to fund operations for at least six months.

Management Comments

"iSpecimens mission is to accelerate life science research, discovery and development with a global marketplace platform that connects researchers to subjects, specimens, and associated data."
"Our vision is to create an Amazon-like global Marketplace of patients, biospecimens, and data for research to improve the quality of human life."
"We are seeking to transform the world of biospecimen procurement much like the way travel websites changed the consumer buying process for flights, hotels, and rental cars."
"We believe with additional investment in technology development resources, we could make significant progress in scaling our iSpecimen Marketplace and, in addition to increased patient and specimen data integration, we expect to continue to improve the matchmaking across the platform and have capabilities such as more direct support for our prospective collections, deeper search and workflow capabilities, increased automation, and direct pricing availability in the platform."
"We believe that seamlessly integrating into their workflow is critical to its use and ongoing success." (referring to supplier integration)
"We believe our approach offers many advantages over a more traditional inventory-based supplier business model where biorepositories take inventory risks, and where turnover and cash conversion cycles can be lengthy, depending on market demand for certain specimen types."
"Management will have broad discretion in the application of the net proceeds, and investors will be relying on our judgment regarding the use of such proceeds."

Industry Context

The document highlights iSpecimen's position in the human biospecimen procurement market, which is described as highly fragmented and inefficient. The company aims to transform this market using a two-sided online marketplace model, similar to how travel websites revolutionized consumer travel booking. The increasing demand for human biospecimens and associated clinical data, driven by advances in technology and the pursuit of precision medicine, underscores the critical role of companies like iSpecimen. The company's model of 'just in time' procurement contrasts with traditional inventory-based biorepositories, offering a potentially more efficient and less risky approach in a market where demand for specific specimen types can fluctuate.

Comparison to Industry Standards

The iSpecimen Marketplace brings new capabilities to a highly fragmented and inefficient biospecimen procurement market, aiming to consolidate the buying experience.
The company seeks to transform biospecimen procurement similar to how travel websites changed consumer buying processes for flights, hotels, and rental cars, implying a move towards greater efficiency and user-friendliness compared to traditional methods.
In contrast to thousands of biospecimen providers relying on email and spreadsheets, iSpecimen's Marketplace offers a more efficient user experience, suggesting a competitive advantage in workflow automation.
The inclusion of competitors' specimens on the iSpecimen Marketplace platform is noted to strengthen its competitive position and value by further de-fragmenting the customer buying experience, indicating a strategy to become a central hub.
The use of biospecimens for biomarker companion diagnostic discovery and development is cited as reducing drug clinical trial costs by 30% to 60% according to Ark Research, positioning iSpecimen's services within a high-value, cost-saving context for the pharmaceutical industry.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Indemnification Policy	The company's second amended and restated bylaws and fourth amended and restated certificate of incorporation provide for indemnification of directors and officers to the fullest extent permitted by Delaware law, covering expenses (including attorneys' fees), judgments, fines, and settlement amounts incurred in connection with legal proceedings.	N/A	Provides significant protection to directors and officers, potentially reducing personal liability and encouraging service, but also means the company bears these costs.
Director Liability Limitation	The fourth amended and restated certificate of incorporation limits director personal monetary liability for breach of fiduciary duty, except for breaches of loyalty, acts not in good faith, intentional misconduct, knowing law violations, unlawful payments, or improper personal benefit.	N/A	Reduces personal financial risk for directors, potentially attracting qualified individuals, but also limits avenues for stockholders to seek monetary damages for certain breaches.

Stakeholder Impact

**Shareholders**: Existing shareholders will experience dilution due to the issuance of new common stock and/or pre-funded warrants. There is also potential for further dilution from outstanding stock options, warrants, and future capital raises. The capital raise aims to improve the company's financial stability, which could benefit shareholders by mitigating the 'going concern' risk.
**Employees**: The ability to retain key employees is identified as a risk. The capital raise, by extending the operational runway, may help ensure job security and continued operations, which is beneficial for employees.
**Customers**: The capital raise is intended to fund technology enhancements and marketing, which could lead to an improved platform experience, deeper search capabilities, and increased automation, ultimately benefiting researchers by making biospecimen procurement easier and more efficient.
**Suppliers**: Increased investment in technology aims to improve supplier engagement and integration into their workflows, making it easier and more fulfilling for healthcare providers to supply specimens. The company's 'just in time' model also reduces inventory risks for suppliers.
**Creditors**: The capital raise directly addresses the 'going concern' warning, which is a significant positive for creditors as it improves the company's ability to meet its financial obligations and continue operations.

Next Steps

Completion of the public offering, expected not later than two business days following the effective date of the registration statement.
Delivery of securities to purchasers upon receipt of investor funds.
Investment of pending funds in short-term, investment grade, interest-bearing securities.
Continued enhancement and improvement of the iSpecimen Marketplace platform based on a user-informed roadmap.
Continued exploration of adjacencies that leverage the platform, including a 'data as a product' model.
Achievement of milestones for SalesStack technology platform acquisition, including $1,000,000 upon completion of build and installation, $700,000 upon full integration, and $700,000 upon completion of customization and one month of post-customization support.
Marketing and advertising services by IR Agency LLC for an initial term of three months, commencing on the closing date of the offering.

Key Dates

Date	Description
2009-07-01	iSpecimen Inc. formed as a Delaware corporation.
2012-09-01	Date of Capital Commitment Agreement.
2014-08-22	Date of Form of Series B Preferred Stock Purchase Agreement.
2017-12-29	Date of Unsecured Convertible Promissory Note issued by the Company to Anna-Maria and Stephen Kellen Foundation, Inc.
2018-08-03	Date of Omnibus Amendment to Unsecured Convertible Notes and Subscription Agreement.
2019-05-01	Date of Second Omnibus Amendment to Unsecured Convertible Notes and Subscription Agreement and First Amendment to Note Subscription Agreements and Secured Promissory Notes.
2019-11-15	Date of Third Omnibus Amendment to Unsecured Convertible Notes and Subscription Agreement and Second Amendment to Note Subscription Agreements and Secured Promissory Notes.
2019-12-31	Entered the regenerative medicine market late 2019.
2020-06-15	Date of Third Amendment to Note Subscription Agreements and Secured Promissory Notes.
2020-09-19	Date of Fourth Omnibus Amendment to Unsecured Convertible Notes and Subscription Agreement.
2020-10-01	Date of Fourth Amendment to Note Subscription Agreements and Secured Promissory Notes.
2021-01-01	Date of Factoring Agreement with Versant Funding, LLC.
2021-03-15	Date of Fifth Amendment to Note Subscription Agreements and Secured Promissory Notes.
2021-08-13	Date of Warrant to Purchase Common Stock issued to Western Alliance Bank.
2021-11-28	Date of Securities Purchase Agreement and Registration Rights Agreement with purchasers.
2022-04-29	Date of Waiver Agreement with Western Alliance Bank.
2022-06-20	Date of First Amendment to Executive Employment Agreements with Christopher Ianelli and Jill Mullan.
2022-10-24	Date of First Amended and Restated Executive Employment Agreement with Benjamin Bielak, and Separation Agreements with Christopher Ianelli and Jill Mullan.
2023-12-31	Fiscal year end for which Wolf & Company, P.C. audited financial statements and issued a 'going concern' warning.
2024-02-13	Company entered into warrant repurchase and termination agreements with certain holders.
2024-10-31	Date of Form of Placement Agency Agreement, Form of Securities Purchase Agreement, and Form of Investor Relations Agreement.
2024-12-13	Date of Engagement Letter between iSpecimen Inc. and Yuying Liang Professional Corp.
2024-12-31	Fiscal year end for which Bush & Associates CPA LLC audited financial statements; also the date for various financial and operational metrics.
2025-01-16	Date of Current Report on Form 8-K filed with the SEC.
2025-01-31	799,631 shares of common stock issued upon exercise of pre-funded warrants during January 2025.
2025-02-24	Date of Current Report on Form 8-K filed with the SEC.
2025-02-28	Date of Current Report on Form 8-K/A (Amendment No. 1) filed with the SEC.
2025-03-11	Date of Current Report on Form 8-K filed with the SEC.
2025-03-13	Date of Wolf & Company, P.C. report on 2023 financial statements (except Note 1, Reverse Stock Split and Note 13, as to which the date is April 14, 2025).
2025-03-31	Period end for Quarterly Report on Form 10-Q.
2025-04-01	171 shares of common stock issued upon vesting of restricted stock units.
2025-04-14	Date of Annual Report on Form 10-K for fiscal year ended December 31, 2024, filed with the SEC.
2025-05-19	Date of Quarterly Report on Form 10-Q for the period ended March 31, 2025, filed with the SEC.
2025-06-05	Date of Current Report on Form 8-K filed with the SEC.
2025-06-24	Date of Current Report on Form 8-K filed with the SEC.
2025-06-27	Date of this S-1/A filing.
2026-12-31	Last day of fiscal year following the fifth anniversary of IPO, after which the company may cease to be an emerging growth company.

Recommendation

hold

Keywords

biospecimens, life science research, biotechnology, healthcare technology, marketplace platform, SEC filing, S-1/A, public offering, common stock, pre-funded warrants, biopharmaceutical, in vitro diagnostics, corporate governance, risk management, financial reporting, going concern, dilution, Nasdaq, ISPC

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.